Navigation Links
Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Date:9/11/2008

SOUTH EASTON, Mass., Sept. 11 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or "the Company") today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Researchers at USAMRIID have recently shown that the use of the Company's patented pressure cycling technology ("PCT") with patent-pending chemical reagents ("ProteoSolve-SB") has resulted in the simultaneous decontamination and extraction of macromolecules (DNA, RNA, proteins, lipids) as well as small molecules from samples containing infectious pathogens. The purpose of this CRADA is to adapt PCT into protocols for the development of medical countermeasures against dangerous pathogens that endanger the warfighter. The CRADA will allow scientists from PBI and USAMRIID to combine resources, experiences, and expertise to help achieve this important goal.

Dr. Chunquin Li, Applications Scientist for Pressure BioSciences, said: "The decontamination and extraction of biomolecules from samples containing dangerous infectious pathogens for subsequent analysis is essential to the development of improved therapies, vaccines, and diagnostics needed to protect soldiers, emergency responders, and others against possible exposure to biological threat agents."

Dr. Nathan Lawrence, Vice President of Marketing at PBI commented: "Research on dangerous pathogens takes place within specially engineered BioSafety Level (BSL) -3 or -4 suites. A rapid procedure to completely decontaminate macromolecules enables the transfer of samples out of containment suites where further studies are more easily conducted. While traditional methods for dec
'/>"/>

SOURCE Pressure BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
2. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Pressure BioSciences, Inc. Announces the Market Release of its PCT-Enhanced Trypsin Digestion Application for Proteomics
5. Healthcare Industry Faces Mounting Pressure to Prevent On-The-Job Violence, Says Veteran Safety and Health Attorney
6. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
7. Four Independent Research Groups Present Data Generated by Pressure Cycling Technology (PCT) at the ASMS Conference on Mass Spectrometry and Allied Topics in Denver, CO
8. InterCure Supports AHA Endorsement of Home Blood Pressure Monitoring
9. International Wound Care Experts, Medline Announce Pressure Ulcer Prevention Consensus Paper
10. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
11. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Tropical birds waited for land crossing between North and South America: UBC study 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 477 percent of European pigs are castrated without anesthetic 2Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 1Nurses from HCA Hospitals Nationwide Rally in Support of MountainView RNs Today 55173 2Smokers Twice As Likely to Get TB 55170 1Smokers Twice As Likely to Get TB 55170 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 1FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 2FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 3FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 4FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 5FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 6FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 7FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 8FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 9FDA Approves XYZAL 28R 29 For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria 55166 10